Expertise in
1
conditions

Dr. Robert J. Jeanfreau

Internal Medicine
Jeanfreau And Jeanfreau LLC
3800 Houma Blvd Ste 335, 
Metairie, LA 
Expertise in
1
conditions
Jeanfreau And Jeanfreau LLC
3800 Houma Blvd Ste 335, 
Metairie, LA 

Overview

Robert Jeanfreau is a primary care provider, practicing in Internal Medicine in Metairie, Louisiana.

Dr. Jeanfreau is highly rated in 1 condition, according to our data. His clinical expertise encompasses Flu, Tardive Dyskinesia, Severe Acute Respiratory Syndrome (SARS), and Tetanus.

He is actively involved in clinical research, co-authoring 18 peer reviewed articles and participating in 12 clinical trials.

Specialties

Internal Medicine

Licenses

Internal Medicine in LA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Louisiana Healthcare Connections
  • HMO
  • MANAGED MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID

Locations

Jeanfreau and Jeanfreau LLC
3800 Houma Blvd Ste 335, Metairie, LA 70006

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase I/II, Observer-blind, Randomised, Placebo-controlled Study to Assess Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)
A Phase I/II, Observer-blind, Randomised, Placebo-controlled Study to Assess Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)
Enrollment Status: Completed
Publish Date: May 08, 2025
Intervention Type: Biological
Study Phase: Phase 2
A Phase III, Randomized, Double-blind, Placebo-controlled Multi-country Study to Demonstrate Efficacy of a Single Dose of Unadjuvanted RSV Maternal Vaccine, Administered IM to Pregnant Women 18 to 49 Years of Age, for Prevention of RSV Associated LRTIs in Their Infants up to 6 Months of Age
A Phase III, Randomized, Double-blind, Placebo-controlled Multi-country Study to Demonstrate Efficacy of a Single Dose of Unadjuvanted RSV Maternal Vaccine, Administered IM to Pregnant Women 18 to 49 Years of Age, for Prevention of RSV Associated LRTIs in Their Infants up to 6 Months of Age
Enrollment Status: Terminated
Publish Date: February 20, 2025
Intervention Type: Biological, Drug
Study Drug: RSV Maternal vaccine
Study Phase: Phase 3
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
Enrollment Status: Completed
Publish Date: June 28, 2024
Intervention Type: Drug
Study Drugs: Galcanezumab, Rimegepant
Study Phase: Phase 4
A Phase III, Randomized, Controlled, Observer-blind Study to Demonstrate Effectiveness, Immunogenicity and Safety of GSK's Meningococcal Group B and Combined ABCWY Vaccines When Administered to Healthy Adolescents and Young Adults
A Phase III, Randomized, Controlled, Observer-blind Study to Demonstrate Effectiveness, Immunogenicity and Safety of GSK's Meningococcal Group B and Combined ABCWY Vaccines When Administered to Healthy Adolescents and Young Adults
Enrollment Status: Completed
Publish Date: March 05, 2024
Intervention Type: Combination product, Biological
Study Phase: Phase 3
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Biological, Other
Study Drug: SARS-CoV-2 rS/Matrix-M1 Adjuvant
Study Phase: Phase 3
A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™-5PSP for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Cervix
A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™-5PSP for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Cervix
Enrollment Status: Completed
Publish Date: July 27, 2023
Intervention Type: Biological, Device
Study Drug: VGX-3100
Study Phase: Phase 3
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
Enrollment Status: Completed
Publish Date: June 22, 2023
Intervention Type: Drug
Study Drugs: Gepotidacin, Nitrofurantoin
Study Phase: Phase 3
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects With Severe Coronavirus Disease 2019 (COVID-19)
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects With Severe Coronavirus Disease 2019 (COVID-19)
Enrollment Status: Completed
Publish Date: May 06, 2023
Intervention Type: Drug
Study Drug: TJ003234
Study Phase: Phase 2/Phase 3
A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)
A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)
Enrollment Status: Completed
Publish Date: December 14, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase II, Randomised, Observer-blind, Placebo Controlled Multi-country Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Intramuscular Dose of GSK Biologicals' Investigational RSV Maternal Unadjuvanted Vaccine (GSK3888550A), in Healthy Pregnant Women Aged 18 to 40 Years and Infants Born to Vaccinated Mothers
A Phase II, Randomised, Observer-blind, Placebo Controlled Multi-country Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Intramuscular Dose of GSK Biologicals' Investigational RSV Maternal Unadjuvanted Vaccine (GSK3888550A), in Healthy Pregnant Women Aged 18 to 40 Years and Infants Born to Vaccinated Mothers
Enrollment Status: Completed
Publish Date: December 13, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
View 9 Less Clinical Trials

18 Total Publications

Immunogenicity and Safety of vYF, a Yellow Fever Vaccine - A Phase 2 Trial.
Immunogenicity and Safety of vYF, a Yellow Fever Vaccine - A Phase 2 Trial.
Journal: The New England journal of medicine
Published: April 08, 2026
Similar Doctors
Expertise in
63
conditions
Dr. Patrick D. Walker
Internal Medicine
Expertise in
63
conditions
Dr. Patrick D. Walker
Internal Medicine
Before you request

Houma Health Clinic Inc

827 Bayou Gardens Blvd, 
Houma, LA 
 (42.0 miles away)
985-853-2343
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Patrick Walker is a primary care provider, practicing in Internal Medicine in Houma, Louisiana. Dr. Walker is highly rated in 63 conditions, according to our data. His clinical expertise encompasses Membranoproliferative Glomerulonephritis, Glomerulonephritis, Membranous Nephropathy, Gastrostomy, and Endoscopy. Dr. Walker is currently accepting new patients.

Expertise in
24
conditions
Dr. Frank J. Rabito
Internal Medicine
Expertise in
24
conditions
Dr. Frank J. Rabito
Internal Medicine

Dimple K Zaveri MD LLC

4315 Houma Blvd, 
Metairie, LA 
 (0.6 miles away)
504-455-4622
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Frank Rabito is a primary care provider, practicing in Internal Medicine in Metairie, Louisiana. Dr. Rabito is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Osteomyelitis, Osteomyelitis in Children, Infectious Arthritis, and Nontuberculous Mycobacterial Lung Disease. Dr. Rabito is currently accepting new patients.

Expertise in
12
conditions
Dr. Swetha R. Kanduri
Internal Medicine
Expertise in
12
conditions
Dr. Swetha R. Kanduri
Internal Medicine

Ochsner Clinic Foundation

1514 Jefferson Hwy, 
New Orleans, LA 
 (4.5 miles away)
504-842-3930
Languages Spoken:
English, Telugu
See accepted insurances
Accepting New Patients

Swetha Kanduri is a primary care provider, practicing in Internal Medicine in New Orleans, Louisiana. Dr. Kanduri is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Hepatorenal Syndrome, Milk-Alkali Syndrome, Hypercalcemia, Interstitial Nephritis, and Kidney Transplant. Dr. Kanduri is currently accepting new patients.

Frequently Asked Questions about Dr. Robert J. Jeanfreau

How do I make an appointment with Dr. Robert J. Jeanfreau?

You can book an appointment with Dr. Robert J. Jeanfreau by calling their office at 504-779-9352. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Robert J. Jeanfreau a top-rated expert for Flu?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Robert J. Jeanfreau is classified as an Advanced expert for Flu, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Robert J. Jeanfreau specialize in?

While Dr. Robert J. Jeanfreau is a Internal Medicine, they have specific expertise in Flu, Tardive Dyskinesia, and Severe Acute Respiratory Syndrome (SARS). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Robert J. Jeanfreau participate in research or clinical trials?

Yes. Dr. Robert J. Jeanfreau has published 18 articles and abstracts on conditions like Flu. You can view a list of Dr. Robert J. Jeanfreau's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Robert J. Jeanfreau accept my insurance?

Dr. Robert J. Jeanfreau accepts most major insurance plans, including Blue Cross Blue Shield and Cigna. We recommend calling the office directly at 504-779-9352 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jeanfreau's expertise for a condition
ConditionClose
      View All 22 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile